These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32280197)

  • 1. Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
    Zhou L; Lin J; Wu G; Chen J; Huang X; Zhang S
    Drug Des Devel Ther; 2020; 14():1257-1262. PubMed ID: 32280197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
    Peng PJ; Cheng H; Ou XQ; Zeng LJ; Wu X; Liu YM; Lin Z; Tang YN; Wang SY; Zhang HY; Chen ZB
    Drug Des Devel Ther; 2014; 8():1083-7. PubMed ID: 25152614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma.
    Zhang S; Chen J; Yang S; Lin S
    Anticancer Drugs; 2016 Aug; 27(7):685-8. PubMed ID: 27088576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
    Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
    Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
    Zhang C; Yu GM; Zhang M; Wu W; Gong LB
    Medicine (Baltimore); 2020 Jan; 99(3):e18892. PubMed ID: 32011517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
    Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
    Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
    BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
    Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
    Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of apatinib combined with S-1 for advanced gastric cancer: A systematic review and meta-analysis.
    Chen X; Wan L; He Y; Zhang Q; Zheng X
    Medicine (Baltimore); 2024 May; 103(21):e38272. PubMed ID: 38787998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
    Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
    Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
    Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
    Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
    Tsujitani S; Fukuda K; Kaibara N
    Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.